24/7 Market News Snapshot 27 March, 2025 – Regulus Therapeutics Inc. (NASDAQ:RGLS)

March 27, 2025

DENVER, Colo., 27 March, 2025 (247marketnews.com) – (NASDAQ:RGLS) are discussed in this article.
Regulus Therapeutics Inc. (RGLS) has reported a significant surge in its stock price, with pre-market trading reaching $1.505, marking a 16.67% increase from the previous day’s close at $1.290. This rise reflects robust investor interest, evidenced by a trading volume of 560.11K shares. Market analysts acknowledge key resistance levels around $1.60 and support near $1.25. The optimistic momentum aligns with recent favorable developments in the company’s therapeutic pipeline, particularly in relation to Autosomal Dominant Polycystic Kidney Disease (ADPKD).

The company’s promising topline results from the fourth cohort of its Phase 1b Multiple Ascending Dose (MAD) study of farabursen have sparked considerable excitement. The study, which evaluated 26 adult patients, found that those receiving a 300 mg fixed dose of farabursen experienced a notable stabilization of height-adjusted total kidney volume (htTKV) over four months, in stark contrast to growth observed in placebo participants. The favorable safety profile of the dosage and the increase in biomarkers PC1 and PC2 highlight farabursen’s effectiveness in halting the progression of kidney growth.

Dr. Preston Klassen, President and Head of Research & Development at Regulus, expressed optimism regarding these findings, reinforcing the belief that the selected dose offers optimal therapeutic exposure. Additionally, with plans for a pivotal Phase 3 trial targeting htTKV set to commence in the third quarter of 2025, the data from this cohort is poised to play a crucial role in further validating farabursen’s potential impact in treating ADPKD.

Jay Hagan, CEO of Regulus Therapeutics, acknowledged the significant contribution of all clinical trial participants and reiterated the company’s commitment to delivering innovative treatments for chronic kidney diseases, aiming to make a substantial difference in patient care globally.

Related news for (RGLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.